RISK-BENEFIT ASSESSMENT OF AMIODARONE IN THE TREATMENT OF CARDIAC-ARRHYTHMIAS

被引：19

作者：

COUNIHAN, PJ

MCKENNA, WJ

机构：

[1] Department of Cardiological Sciences, St George’S Hospital Medical School, London, SW17 ORE, Cranmer Terrace

来源：

DRUG SAFETY | 1990年 / 5卷 / 04期

关键词：

D O I：

10.2165/00002018-199005040-00005

中图分类号：

R1 [预防医学、卫生学];

学科分类号：

1004 ; 120402 ;

摘要：

Cardiac arrhythmias are a cause of significant morbidity and mortality in patients with cardiac disease, and thus represent a major management problem. The recognition that antiarrhythmic drugs have the potential to aggravate as well as to attenuate arrhythmias has prompted clinicians to reconsider treatment strategies and weigh the benefits of treatment against the risks. In this context, amiodarone has emerged as an effective antiarrhythmic agent and when used at the lowest effective dose has an acceptable side effect profile. This review focuses on the current clinical usage of amiodarone in a broad variety of cardiac arrhythmias, and addresses the risk-benefits arising from its use. It further discusses the current position of amiodarone in the management of sudden cardiac death. © 1990, Adis International Limited. All rights reserved.

引用

页码：286 / 304

页数：19

共 114 条

[1]

Ada P.C., Holt D.W., Storey G.C.A., Morley A.R., Campbell R.W.F., Amiodarone and its desethyl metabolite: tissue distribution and morphological changes during chronic therapy, Circulation, 72, pp. 1064-1075, (1985)

[2]

Alfonso F., Frenneaux M., McKenna W.J., Clinical sustained monomorphic ventricular tachycardia in hypertrophic cardiomyopathy: association with left ventricular apical aneurysm, British Heart Journal, 61, pp. 178-181, (1989)

[3]

Anastasiou-Nana M., Levis G.M., Moulopoulos S., Pharmacokinetics of amiodarone after intravenous and oral administration, International Journal of Clinical Pharmacology Therapy and Toxicology, 20, pp. 524-529, (1982)

[4]

Andreasen F., Agerback H., Bjerregaard P., Gotzsche H., Pharmacokinetics of amiodarone after intravenous and oral administration, European Journal of Clinical Pharmacology, 19, pp. 293-299, (1981)

[5]

Beukema W.P., Graboys T.B., Spontaneous disappearance of blue-grey pigmentation during amiodarone therapy (out of the blue), American Journal of Cardiology, 62, pp. 1146-1147, (1988)

[6]

Bonati M., Galletti F., Volpi A., Cumetti C., Tognan G., Amiodarone in patients on long term dialysis, New England Journal of Medicine, 308, (1983)

[7]

Borgreffe M., Leibner M., Briethardt G., Clinical electrophysiologic effects of combining Class I antiarrhythmic effects with amiodarone in drug refractory tachycardia, Circulation, 74, pp. 11-224, (1986)

[8]

Brown A.K., Holt D.W., Anderson V., A practical regimen for intravenous amiodarone, British Journal of Clinical Practice, 40, 44, pp. 135-138, (1986)

[9]

Burger A., Dinichett C., Nicod P., Jenny N., LeMarchand B.P., Effect of amiodarone on serum triiodothyronine, reverse triiodothyronine, thyroxine and thyrotropin: a drug influencing peripheral metabolism of thyroid hormones, Journal of Clinical Investigation, 58, pp. 255-259, (1976)

[10]

Burkart F., Pfisterer M., Kiowski W., Burckhardt D., Follath F., Improved survival of patients with asymptomatic ventricular arrhythmias after myocardial infarction with amiodarone: a randomised, controlled trial, Circulation, 80, pp. 11-119, (1989)

← 1 2 3 4 5 6 7 8 9 10 →